MIAMI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of ...

A study using the mutant fruitfly sleepless confirmed that the enzyme GABA transaminase, a target of some epilepsy drugs, contributes to sleep loss. The findings shed light on mechanisms that may be ...

A major mystery in epilepsy research has been why infants are more prone to seizures than adults and how those seizures progress to chronic epilepsy. Now, researchers have discovered that central to ...

New research from McLean Hospital and the Harvard Stem Cell Institute has shown that stem cell therapy reduces seizures in mice. Researchers used an animal model to transplant seizure-inhibiting, ...

Ovid Therapeutics' OV329 shows promise in early Phase 1 data for treating pharmacoresistant epilepsy, boasting superior pharmacokinetics and safety profiles. Financials are strong with a robust ...

Researchers conducted experiments on the hippocampus of neonatal rats and mice, quite similar to the one of a human fetus at the second half of pregnancy period. Hence it will be possible make precise ...

The brain is a precision instrument. Its function depends on finely calibrated electrical activity triggering the release of chemical messages between neurons. But sometimes the brain’s careful ...

Antiepileptic drugs (AEDs) protect against seizures by modulation of voltage-gated sodium and calcium channels, enhancement of GABA A (γ-aminobutyric acid, type A) receptor-mediated synaptic ...

Scientists have, for the first time, determined the structure of a key protein that transports a neurotransmitter responsible for reducing the activity of neurons in the brain, providing details at ...

Shares of Ovid Therapeutics OVID rallied 39.2% primarily driven by the encouraging top-line data readout from an early-stage study of the company’s lead investigational candidate, OV329. The candidate ...